This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Bullous Diseases  • Pemphigoid  • Immunologic Disorders  • Alert me on articles by topic

Arch Dermatol. 2002;138:404.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

THE SEARCH for an effective and safe therapy for bullous pemphigoid (BP) is important. Compared with other cutaneous disorders, BP has a relatively high morbidity and may occasionally be fatal. It most frequently affects the elderly, who are especially susceptible to the adverse effects of systemic drugs such as corticosteroids. The first-line agents that are used by most dermatologists are systemic corticosteroids. In mild cases of BP, there is a tendency to use potent topical steroids or anti-inflammatory agents other than corticosteroids, such as oral antibiotics, nicotinamide, or dapsone. In rare instances, nonsteroidal immunosuppressive therapy is instituted.

Khumalo et al¹ review BP treatments in this issue of the ARCHIVES. In their literature review, they identify, outline, discuss, and critique effectively 6 randomized controlled trials comprising 293 patients. None of the trials used a placebo group. In the first study, there was no difference in the effectiveness of methylprednisolone compared with . . . [Full Text of this Article]

RELATED ARTICLE

A Systematic Review of Treatments for Bullous Pemphigoid
Nonhlanhla P. Khumalo, Dedeé F. Murrell, Fenella Wojnarowska, and Gudula Kirtschig
Arch Dermatol. 2002;138(3):385-389.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prediction of Survival for Patients With Bullous Pemphigoid: A Prospective Study
Joly et al.
Arch Dermatol 2005;141:691-698.
ABSTRACT | FULL TEXT